REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to […]

Deriv’s UK team celebrates the Best Place to Work win UK office has also received a renewal for its Great Place to Work® certifications alongside six other Deriv offices Celebrates 25 years of building a positive workplace culture Deriv’s UK team celebrates the Best Place to Work win LONDON, Sept. 03, 2024 (GLOBE NEWSWIRE) — Deriv, […]